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anjay B. Pandya, MD,* Young-Hak Kim, MD,† Sheridan N. Meyers, MD,*
harles J. Davidson, MD,* James D. Flaherty, MD,* Duk-Woo Park, MD,†
nuj Mediratta, MD,* Karen Pieper, MS,‡ Eric Reyes, MS,‡ Robert O. Bonow, MD,*
eung-Jung Park, MD,† Nirat Beohar, MD*
hicago, Illinois; Seoul, Korea; and Durham, North Carolina
bjectives We undertook a meta-analysis to assess outcomes for drug-eluting stents (DES) and
are-metal stents (BMS) in percutaneous coronary intervention for unprotected left main coronary
rtery (ULMCA) stenosis.
ackground Uncertainty exists regarding the relative performance of DES versus BMS in percutane-
us coronary intervention for unprotected left main coronary stenosis.
ethods Of a total of 838 studies, 44 met inclusion criteria (n  10,342). The co-primary end points
ere mortality, myocardial infarction (MI), target vessel/lesion revascularization (TVR/TLR), and major
dverse cardiac events (MACE: mortality, MI, TVR/TLR).
esults Event rates for DES and BMS were calculated at 6 to 12 months, at 2 years, and at 3 years.
rude event rates at 3 years were mortality (8.8% and 12.7%), MI (4.0% and 3.4%), TVR/TLR (8.0%
nd 16.4%), and MACE (21.4% and 31.6%). Nine studies were included in a comparative analysis
n  5,081). At 6 to 12 months the adjusted odds ratio (OR) for DES versus BMS were: mortality
.94 (95% conﬁdence interval [CI]: 0.06 to 15.48; p  0.97), MI 0.64 (95% CI: 0.19 to 2.17; p  0.47),
VR/TLR 0.10 (95% CI: 0.01 to 0.84; p  0.01), and MACE 0.34 (95% CI: 0.15 to 0.78; p  0.01). At
years, the OR for DES versus BMS were: mortality 0.42 (95% CI: 0.28 to 0.62; p  0.01), MI 0.16
95% CI: 0.01 to 3.53; p  0.13), and MACE 0.31 (95% CI: 0.15 to 0.66; p  0.01). At 3 years, the OR
or DES versus BMS were: mortality 0.70 (95% CI: 0.53 to 0.92; p  0.01), MI 0.49 (95% CI: 0.26 to
.92; p  0.03), TVR/TLR 0.46 (95% CI: 0.30 to 0.69; p  0.01), and MACE 0.78 (95% CI: 0.57 to 1.07;
 0.12).
onclusions Our meta-analysis suggests that DES is associated with favorable outcomes for mortal-
ty, MI, TVR/TLR, and MACE as compared to BMS in percutaneous coronary intervention for unpro-
ected left main coronary artery stenosis. (J Am Coll Cardiol Intv 2010;3:602–11) © 2010 by the
merican College of Cardiology Foundation
rom the *Feinberg School of Medicine, Northwestern University, Chicago, Illinois; †University of Ulsan College of Medicine,
eoul, Korea; and the ‡Duke Clinical Research Institute, Durham, North Carolina.anuscript received March 3, 2010, accepted March 18, 2010.
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603nprotected left main coronary artery stenosis (LMCA) is
ssociated with poor clinical outcomes. Studies have shown
mproved long-term outcomes in those who undergo surgi-
al revascularization as compared to optimal medical ther-
py alone (1,2). This is the basis for the American College
f Cardiology/American Heart Association class I recom-
endation for coronary artery bypass graft surgery (CABG)
n patients with 50% left main stenosis (3).
See page 642
Early percutaneous attempts at revascularization with
alloon-only angioplasty were associated with suboptimal clin-
cal outcomes (4). This led to an American College of
ardiology/American Heart Association Class III (contrain-
icated) guidelines recommendation for percutaneous coronary
ntervention (PCI) in CABG-eligible patients (5). The subse-
uent advent of coronary stents, which reduced periprocedural
isks and improved clinical outcomes, renewed interest in
nprotected LMCA PCI. This interest was further fueled by
he subsequent introduction of drug-eluting stents (DES),
hich led to substantially lower rates of restenosis in coronary
esions (6,7). Based on improved clinical outcomes, the most
ecent American College of Cardiology/American Heart As-
ociation guidelines have given unprotected LMCA PCI a
lass IIb recommendation (8).
However, there remains some clinical uncertainty over the
deal stent type for unprotected LMCA PCI. The use of DES
n the left main position is considered an off-label application;
revious studies have identified increased adverse events for
uch off-label applications (9). Additionally, although the
eduction in restenosis seen with DES use is particularly
ttractive for unprotected LMCA PCI, the large caliber of
ost left main arteries could attenuate this benefit. Finally,
oncern exists over potentially increased rates of late stent
hrombosis with DES, which has serious implications in
nprotected LMCA PCI (10).
We performed a meta-analysis of the current literature to
ssess outcomes of PCI in unprotected LMCA and to
ompare the relative performance of DES and bare-metal
tents (BMS) in this application.
ethods
earch strategy. PubMed, clinicaltrials.gov, and BioMed
entral databases were searched from January 2000 to
eptember 2009; there were no language restrictions. Search
erms included “left main,” “coronary,” “intervention,” and
stenting.” Citations were screened and evaluated using the
stablished inclusion/exclusion criteria at the abstract level
y 2 operators (S.P. and N.B.), and relevant studies were
etrieved as full manuscripts. Inclusion criteria were: 1)
nvolving unprotected left main disease; 2) involving BMS er DES; and 3) involving at least 20 patients in the overall
tudy cohort. Exclusion criteria were defined as: 1) unpub-
ished studies; 2) abstract only; 3) angioplasty without
tenting; 4) ST-segment elevation myocardial infarction; 5)
ardiogenic shock; 6) experimental devices; 7) non-English
tudies; and 8) studies not reporting relevant clinical out-
omes. Data regarding patient demographics and clinical
utcomes were then entered into a database.
nd points. The co-primary end points were mortality,
yocardial infarction (MI), target vessel/target lesion revas-
ularization (TVR/TLR), and major adverse cardiac events
MACE), which were defined as mortality, MI, and TVR/
LR. These end points were reported for the following
ime periods post-PCI: 6 to 12 months, 2 years, and 3 years.
ata for all end points at each time period were not
vailable for every study.
tatistical analysis. Crude event
ates were reported for mortality,
I, and TVR/TLR for both
ES and BMS. Because these
stimates were based, in part, on
tudies for which a causal link
etween stent type and outcome
as not established, direct com-
arison of rates is not appropri-
te, and rates can only be seen as
escriptive in nature. Subsequent
omparative analysis was per-
ormed evaluating studies that
rovided adjusted outcomes on
elevant end points or were ran-
omized according to stent types;
dds ratios (OR) were reported
or this analysis. When both haz-
rd ratios (HR) and OR were
eported as end points across tri-
ls, they were combined, assum-
ng that the follow-up was fairly
omplete (and thus the HR would be similar to the expected
R). Similarly, Kaplan-Meier rates and percentages were
ombined when 1 of the 2 was not available for an end point.
everal end points did not meet the assumption of homoge-
eity of rates across studies, and thus random effects modeling
echniques were used to combine rates and calculate confidence
ntervals. Comprehensive Meta Analysis software, version
.2.048 (Biostat Inc., Englewood, New Jersey), was used for all
nalyses (11).
esults
atabase searches retrieved an initial 838 studies, of which
5 were deemed relevant; 31 of these studies were eventually
xcluded (12–42). A final 44 studies meeting inclusion/
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LMCA  left main coronary
artery stenosis
MACE  major adverse
cardiac events
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
TLR  target lesion
revascularization
TVR  target vessel
revascularizationxclusion criteria were included in the analysis (43–86),
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604onsisting of 10,342 patients (Fig. 1). Studies fell into
eneral categories involving: 1) use of only BMS (43–47); 2)
se of only DES (48–68); 3) comparative studies of BMS
ersus DES (56,69–80); or 4) comparison studies of PCI
ersus CABG (81–86) (Table 1).
Patient demographics in the group undergoing BMS
lacement were generally similar to those undergoing DES
lacement (Table 2). There was incomplete reporting of
aseline demographics across studies. Medication profiles,
ncluding duration of antiplatelet drug therapy, were incon-
istently reported.
Estimates of rates for mortality, MI, and TVR/TLR at
ach of the 3 recorded time points are displayed in Table 3.
he rates of events are numerically higher for patients
reated with BMS for most end points, at most time points.
owever, without adjustment, the significance and/or rel-
vance of the differences noted cannot be fully determined.
Figure 1. Methods
Diagram outlining inclusion/exclusion process for studies incorporated into the
nary angioplasty; STEMI  ST-segment elevation myocardial infarction.s expected, the overall rates of events are higher in patients tndergoing unprotected LMCA PCI than in conventional
CI patients.
Subsequent analysis was performed on those studies
omparing DES and BMS and providing either adjusted
vent rates, or randomization according to stent type. Of the
2 comparative studies, 9 studies (33,69–72,74,77–79) re-
orted relevant end points, consisting of 5,081 patients
Table 4). Most utilized propensity scoring for adjustment.
omparative event estimates for DES versus BMS were
alculated (Table 5). At 6 to 12 months, the OR for
ortality was 0.94 (95% confidence interval [CI]: 0.06 to
5.48; p  0.97) and for MI was 0.64 (95% CI: 0.19 to
.17; p  0.47). The OR clearly favored DES for TVR/
LR (0.10; 95% CI: 0.01 to 0.84; p  0.01) and MACE
0.34; 95% CI: 0.15 to 0.78; p  0.01) at 6 to 12 months.
t 2 years, the OR favored DES for mortality (0.42; 95%
I: 0.28 to 0.62; p 0.01) and MACE (0.31; 95% CI: 0.15
overall and comparative analyses. PTCA  percutaneous transluminal coro-ﬁnalo 0.66; p  0.01); the OR for MI did not reach statistical
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605Table 1. Included Studies
First Author (Ref. #) Year Design Stent Type n
DES
(n)
BMS
(n) Location
Follow-Up
(Months)
BMS-only studies: 5
Black et al. (43) 2001 Retrospective cohort study BMS 92 0 92 Europe 7 5
Kelley et al. (44) 2003 Retrospective cohort study BMS 43 0 43 U.S./Europe 12
Lee et al. (45) 2007 Prospective cohort study BMS 187 0 187 Asia 71 26
Silvestri et al. (46) 2000 Prospective cohort study BMS 140 0 140 Europe 12
Takagi et al. (47) 2002 Prospective cohort study BMS 64 0 64 Europe 31 23
DES-only studies: 21
Agostoni et al. (48) 2005 Retrospective cohort study DES 58 58 0 Europe 15
Arampatzis et al. (49) 2003 Retrospective cohort study DES 31 31 0 Europe 5.1 1.8
Chieffo et al. (50) 2007 Retrospective cohort study DES 147 147 0 U.S./Asia/ Europe 30 10
Chieffo et al. (51) 2008 Retrospective cohort study DES 731 731 0 U.S./Asia/ Europe 29 13
Cherradi et al. (52) 2008 Prospective cohort study DES 101 101 0 Europe 12 3
de Lezo et al. (53) 2004 Prospective cohort study DES 52 52 0 Europe 12
Ge et al. (54) 2007 Retrospective cohort study DES 70 70 0 Asia/Europe 12
Khattab et al. (55) 2007 Prospective cohort study DES 82 82 0 Europe 36
Kim et al. (56) 2006 Retrospective cohort study DES 116 116 0 Asia 18
Kim et al. (57) 2008 Retrospective cohort study DES 63 63 0 U.S. 12 8
Lee et al. (58) 2005 Nonrandomized study (SES vs. PES) DES 54 54 0 Asia 6
Lozano et al. (59) 2004 Prospective cohort study DES 42 42 0 Europe 11
Mehilli et al. (60) 2009 Randomized controlled trial (SES vs. PES) DES 607 607 0 Europe 24
Meliga et al. (61) 2008 Retrospective cohort study DES 358 358 0 U.S./Europe 36
Migliorini et al. (62) 2006 Prospective cohort study DES 101 101 0 Europe 10 6
Price et al. (63) 2006 Prospective cohort study DES 50 50 0 U.S. 9
Sanmartin et al. (64) 2007 Prospective cohort study DES 100 100 0 Europe 12
Sheiban et al. (65) 2007 Prospective cohort study DES 85 85 0 Europe 20 7
Vaquerizo et al. (66) 2009 Prospective cohort study DES 291 291 0 Europe 24
Vecchio et al. (67) 2007 Prospective cohort study DES 114 114 0 Europe 17 9
Wood et al. (68) 2008 Retrospective cohort study DES 100 100 0 U.S. 28
BMS and DES studies: 12
Cheiffo et al. (69) 2005 Nonrandomized study DES vs. BMS 149 85 64 Europe 6
Erglis et al. (70) 2007 Randomized controlled trial DES vs. BMS 103 53 50 Australia 6
Gao et al. (71) 2008 Nonrandomized study DES vs. BMS 424 220 224 Asia 15
Han et al. (72) 2009 Nonrandomized study DES vs. BMS 287 178 109 Asia 35 14
Hertting et al. (73) 2008 Nonrandomized study DES vs. BMS 54 16 38 Europe 24
Kim et al. (74) 2009 Nonrandomized study DES vs. BMS 1,217 864 353 Asia 36
Palmerini et al. (75) 2008 Nonrandomized study DES vs. BMS 1,453 1,111 342 Europe 24
Park et al. (76) 2005 Nonrandomized study DES vs. BMS 123 102 121 Asia 12
Schrale et al. (77) 2008 Retrospective cohort study DES and BMS 100 55 45 Europe 21 14
Tamburino et al. (78) 2009 Nonrandomized study DES vs. BMS 849 611 238 Europe 36
Tamburino et al. (79) 2009 Nonrandomized study DES vs. BMS 479 334 145 Europe 36
Wood et al. (80) 2005 Nonrandomized study DES vs. BMS 161 61 100 U.S. 12
PCI/CABG studies: 6
Buszman et al. (81) 2008 Randomized controlled trial CABG vs. PCI 52 18 34 Europe 28 10
Chieffo et al. (82) 2006 Nonrandomized study CABG vs. DES 107 107 0 Europe 12
Makikallio et al. (83) 2008 Nonrandomized study CABG vs. DES 49 49 0 Europe 12 6
Palmerini et al. (84) 2006 Nonrandomized study CABG vs. PCI 157 94 63 Europe 14
Sanmartin et al. (85) 2007 Nonrandomized study CABG vs. DES 96 96 0 Europe 13 8
Seung et al. (86) 2008 Randomized controlled trial CABG vs. PCI 603 396 207 Asia 34BMS bare-metal stent(s); CABG coronary artery bypass graft; DES drug-eluting stent(s); PCI percutaneous coronary intervention.
s
f
l
m
9
C
r
p
D
P
f
a
r
h
H
L
t
fi
s
f
a
e
r
a
i
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 6 , 2 0 1 0
J U N E 2 0 1 0 : 6 0 2 – 1 1
Pandya et al.
DES Versus BMS in Unprotected Left Main PCI
606ignificance (0.16; 95% CI: 0.01 to 3.53; p 0.13). The OR
or TVR/TLR at 2 years could not be estimated due to a
ack of reported data. Findings at 3 years favored DES for
ortality (0.70; 95% CI: 0.53 to 0.92; p  0.01), MI (0.49;
Table 2. Baseline Patient Demographics for Studies Included in the
Overall Analysis
DES BMS
n Percent (95% CI) n Percent (95% CI)
Age, yrs* 4,768 67.5 (65.8–69.3) 1,621 67.9 (66.0–69.7)
Men 6,464 74 (73–75) 2,091 71 (69–73)
DM 6,691 28 (27–29) 2,170 22 (20–23)
Insulin-dependent DM 85 11.0 (4.2–17.8) 63 8.9 (1.9–15.9)
Hypertension 6,297 65 (64–67) 2,032 53 (51–55)
Hypercholesterolemia 6,111 58 (57–59) 1,892 39 (36–41)
History of prior MI 3,036 23 (21–24) 1,165 12 (10–14)
History of PCI 1,912 19 (18–21) 794 13 (10–15)
COPD 1,962 9.4 (7.9–10.9) 996 1.6 (0.8–2.4)
Renal insufﬁciency 3,570 7.7 (6.8–8.6) 1,241 4.5 (3.4–5.6)
Peripheral arterial
disease
1,168 6.8 (5.5–8.2) 560 0.9 (0.03–1.9)
*Age is represented as mean (95% CI). n refers to the number of patients within the studies who
contributed to the estimate of interest. Rates are the estimated percent of patients with the
characteristic and associated 95% confidence intervals (CIs).
COPD  chronic obstructive pulmonary disease; DM  diabetes mellitus; MI  myocardial
infarction; other abbreviations as in Table 1.
Table 3. Estimated Cumulative Event Rates by Stent
Stent Type 6–12 Mo
Mortality DES 5.94%
(4.73%–7.44
n 2,6
BMS 7.24%
(3.51%–14.3
n 763
MI DES 6.26%
(4.71%–8.27
n 2,3
BMS 9.97%
(6.09%–15.9
n 157
TVR/TLR DES 7.83%
(5.95%–10.2
n 2,2
BMS 16.95%
(12.92%–21.
n 985
MACE DES 15.87%
(12.93%–19.
n 2,5
BMS 39.31%
(31.68%–47.
n 554
n refers to the number of patientswithin the studieswho contributed t
event and associated 95% CIs.
MACEmajor adverse cardiac events; TLR target lesion revascular1 and 2.5% CI: 0.26 to 0.92; p 0.03), and TVR/TLR (0.46; 95%
I: 0.30 to 0.69; p  0.01); the OR for MACE did not
each statistical significance (0.78; 95% CI: 0.57 to 1.07;
 0.12).
iscussion
ercutaneous coronary intervention is increasingly being per-
ormed for lesions previously considered contraindicated, such
s unprotected LMCA. Given the lower rates of restenosis
eported with DES in PCI of standard coronary lesions, there
as been a trend toward their use in unprotected LMCA PCI.
owever, the superiority of DES over BMS for unprotected
MCA has not been clearly established.
We reviewed the literature on unprotected LMCA PCI
o compare outcomes between DES and BMS. We identi-
ed 44 studies involving PCI for unprotected LMCA as a
ource for crude event rates. Crude event rates were lower
or DES than BMS for mortality, TVR/TLR, and MACE
t 6 to 12 months, 2 years, and 3 years, but appeared
quivalent for MI at these same time points. However, these
ates are unadjusted, rendering them prone to selection bias
nd confounding.
To address this, we performed a subsequent analysis
nvolving studies that provided adjusted event rates or
andomized patients according to stent type (DES vs.
in the Overall Analysis
2 Years 3 Years
7.89%
(6.07%–10.20%)
n 4,430
8.80%
(6.20%–12.34%)
n 2,912
14.14%
(8.96%–21.62%)
n 1,266
12.71%
(6.94%–22.15%)
n 959
3.90%
(1.98%–7.55%)
n 2,182
4.04%
(2.33%–6.91%)
n 2,516
3.06%
(1.18%–7.69%)
n 607
3.43%
(1.87%–6.21%)
n 752
10.20%
(8.55%–12.13%)
n 4,772
8.03%
(5.62%–11.37%)
n 2,912
16.15%
(13.93%–18.66%)
n 1241
16.40%
(12.23%–21.64%)
n 959
18.99%
(14.92%–23.86%)
n 2,623
21.43%
(14.85%–29.91%)
n 1,652
32.69%
(17.72%–52.26%)
n 441
31.60%
(23.15%–41.47%)
n 399
timate of interest. Rates are the estimated percent of patientswith the
TVR target vessel revascularization; other abbreviations as in TablesType
nths
%)
91
3%)
%)
56
0%)
4%)
57
92%)
32%)
93
50%)
o the es
ization;
Table 4. Comparative Studies of DES Versus BMS
First Author (Ref. #) Design Method of Adjustment
DES
(n)
BMS
(n)
Follow-Up
(Months)
Adjusted Point Estimate at Follow-Up
Mortality MI TVR/TLR MACE
Chieffo et al. (69) Nonrandomized study Propensity score matching 85 64 6 N/A N/A OR: 0.28
(0.09–0.81)
p 0.01
OR: 0.27
(0.09–0.73)
p 0.007
Erglis et al. (70) Randomized controlled
trial
Randomization 53 50 6 OR: 0.94
(0.06–15.48)
p 1.00
OR: 0.64
(0.19–2.17)
p 0.47
OR: 0.10
(0.01–0.84)
p 0.01
OR: 0.36
(0.13–0.96)
p 0.04
Gao et al. (71) Prospective cohort study
(DES compared with
historical BMS cohort)
Propensity score matching 220 224 15 N/A N/A N/A OR: 0.49
(0.26–0.94)
p 0.032
Han et al. (72) Prospective cohort study Propensity score matching 178 109 35 14 OR: 0.25
(0.08–0.81)
p 0.01
OR: 0.16
(0.01–3.53)
p 0.13
OR: 0.26
(0.08–0.83)
p 0.001
OR: 0.23
(0.09–0.56)
p 0.001
Kim et al. (74) Prospective cohort study Weighting with propensity
score
864 353 36 HR: 0.86
(0.50–1.47)
p 0.569
N/A HR: 0.32
(0.17–0.61)
p 0.001
HR: 0.81
(0.54–1.21)
p 0.31
Palmerini et al. (33) Nonrandomized study Propensity score as a
covariate
1,111 342 24 HR: 0.48
(0.32–0.74)
p 0.002
N/A N/A N/A
Schrale et al. (77) Retrospective cohort
study
Multivariate Cox
regression
55 45 21 14 HR: 0.23
(0.06–0.91)
p 0.034
N/A N/A N/A
Tamburino et al. (78) Nonrandomized study Propensity score matching 611 238 36 HR: 0.75
(0.52–1.12)
p 0.17
HR: 0.49
(0.26–0.92)
p 0.03
HR: 0.46
(0.29–0.74)
p 0.001
N/A
Tamburino et al. (79) Nonrandomized study Propensity score matching 334 145 36 HR: 0.51
(0.30–0.86)
p 0.01
N/A HR: 0.79
(0.33–1.90)
p 0.39
HR: 0.73
(0.44–1.21)
p 0.22
n refers to the number of patients within the studies who contributed to the estimate of interest. Odds ratios and hazard ratios are reported with 95% CIs.
HR hazard ratio; OR odds ratio; other abbreviations as in Tables 1 to 3.
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608MS). Although event rates at 6 to 12 months favored
ES, the sample size was small, involving predominantly
study (70). At 2 and 3 years post-PCI, the sample size
as larger, and improved outcomes with DES over BMS
ere observed for mortality, MI, TVR/TLR, and
ACE. Statistically significant differences were observed
n most cases.
Although the finding of lower TVR/TLR rates is con-
istent with the known performance of DES, no study to
ate has shown a consistent mortality benefit with DES
ver BMS in unprotected LMCA PCI. The reason for the
ower mortality rate in the DES group seen in our meta-
nalysis is unclear. It may be that DES, with known lower
ates of restenosis, provides a true advantage over BMS. In
he critical left main position, a small or moderate degree of
estenosis could theoretically precipitate critical ischemia.
lternatively, this finding could be due to methodological
ssues. Selection bias may have favored DES: patients with
ewer medical comorbidities may have preferentially under-
one DES placement. A review of overall patient demo-
raphics in our analysis does not support this, as similar
ates of cardiac risk factors were found between both groups
Table 2). An alternative explanation may relate to a
rocedural learning curve, as operators may have become
ore technically proficient at unprotected LMCA PCI by
he time DES were favored. Finally, as medication profiles
t baseline and follow-up were not consistently reported, it
s possible that the benefit seen with DES could be due, in
Table 5. Cumulative OR for Comparative Studies (DES Versus BMS)
Time
Contributing Studies
First Author (Ref. #)
Mortality 6–12 months Erglis et al. (70)
2 yrs Han et al. (72)
Palmerini et al. (33)
Schrale et al. (77)
3 yrs Kim et al. (74)
Tamburino et al. (78)
Tamburino et al. (79)
MI 6–12 months Erglis et al. (70)
2 yrs Han et al. (72)
3 yrs Tamburino et al. (78)
TVR/TLR 6–12 months Erglis et al. (70)
2 yrs No studies
3 yrs Kim et al. (74)
Tamburino et al. (78)
Tamburino et al. (79)
MACE 6–12 months Chieffo et al. (69)
Erglis et al. (70)
2 yrs Gao et al. (71)
Han et al. (72)
3 yrs Kim et al. (74)
Tamburino et al. (79)
n refers to the number of patients within the studies who contributed to the estimate of interest. O
Abbreviations as in Tables 1 to 4.art, to a longer duration of dual antiplatelet drug therapy as oompared with BMS. Similarly, patients deemed to be poor
andidates for long-term dual or triple antiplatelet therapy
ay have been denied treatment with DES.
A recent meta-analysis of patients undergoing DES for
nprotected LMCA by Biondi-Zoccai et al. (87) noted
imilar findings, reporting an adjusted OR of 0.34 for both
ACE and TVR, favoring DES over BMS. This meta-
nalysis was performed through 2006 and included far fewer
atients than our analysis (206 DES patients, 190 BMS
atients). Since our analysis was performed, Buszman et al.
88) have reported on the long-term follow-up of a group of
52 patients from the LE MANS (Left Main Coronary
rtery Stenting) registry. Their results mirror ours. Un-
atched analysis showed a significantly lower rate of major
dverse cardiovascular or cerebral events with DES as
ompared with BMS at 4-year follow-up (14.9% vs. 25.9%,
 0.039); subsequent propensity matched analysis showed
imilar results. Buszman et al. (88) noted that mortality
ates favored DES, although this did not reach statistical
ignificance (9.6% vs. 13.3%, p  NS). In a subgroup of
atients with distal unprotected LMCA, however, DES,
hen compared with BMS, was associated with a statisti-
ally significant lower mortality rate (p  0.03). Results
rom the left main subset of the SYNTAX (Synergy
etween Percutaneous Coronary Intervention with Taxus
nd Cardiac Surgery) trial (89) were presented at
ranscatheter Cardiovascular Therapeutics 2008 confer-
nce. Reported 12-month DES event rates were similar to
S (n) BMS (n) OR (95% CI) p Value
53 50 0.94 (0.06–15.48) 0.97
344 496 0.42 (0.28–0.62) 0.01
809 736 0.70 (0.53–0.92) 0.01
53 50 0.64 (0.19–2.17) 0.47
178 109 0.16 (0.01–3.53) 0.13
611 238 0.49 (0.26–0.92) 0.03
53 50 0.10 (0.01–0.84) 0.01
— — — —
809 736 0.46 (0.30–0.69) 0.01
138 114 0.34 (0.15–0.78) 0.01
398 333 0.31 (0.15–0.66) 0.01
198 498 0.78 (0.57–1.07) 0.12
os (ORs) are reported with 95% CIs.DE
1,
1,
1,
1,
dds ratiur cumulative crude estimates, with a rate of 4.2% for
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609ortality, 4.3% for MI, and 15.8% for major cardiac or
erebrovascular adverse events (90). As these results have yet
o be published, they were not included in our analysis. The
YNTAX study did not include a BMS arm and thus would
ot influence our comparative analysis.
Currently, there are no large, randomized controlled clinical
rials comparing DES to BMS in unprotected LMCA. Two
ngoing studies comparing PCI with DES to CABG for
nprotected LMCA (PRECOMBAT [Premier of Random-
zed Comparison of Bypass Surgery versus Angioplasty Using
irolimus-Eluting Stent in Patients with Left Main Coronary
rtery Disease] and the recently announced EXCEL trial
Evaluation of Xience Prime versus Coronary Artery Bypass
urgery for Effectiveness of Left Main Revascularization]) do
ot include a comparison with BMS. Therefore, our meta-
nalysis may offer evidence to guide clinical practice.
tudy limitations. Our study has clear limitations. The
imitations of the meta-analytical approach are well known
nd documented (91); the meta-analytical approach with
bservational data is even more fraught with limitations
92). The inclusion of only published studies makes our
nalysis prone to publication bias. Our results, particularly
he crude event rates, are prone to confounding and selec-
ion bias and thus direct comparison of these overall rates
as not performed. We did not have data for all studies at
ach time period; therefore, this limits comparison of rates
cross time within a specific end point. Finally, we were
nable to control for the specific type of DES or BMS used,
s some studies suggest heterogeneous outcomes within the
tent types.
onclusions
he results of this meta-analysis suggest that DES is
ssociated with favorable outcomes as compared with BMS
n unprotected LMCA PCI. The improved outcomes ob-
erved when DES is compared with BMS support a
ontinued re-evaluation of the role of PCI for the treatment
f unprotected LMCA.
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